2nd Annual Pharma Corporate Communications Conference

9th & 10th April, 2008
Rome, Italy
The modern business world is based on communication. Corporate communication is used to shape the strategy of the company and communicate it internally and externally with major stakeholders. Pharmaceutical industry is a very special case when it comes to communication with the public. The industry has recently been challenged by lack of trust from the side of consumers. Reputation has become a major issue and companies need to move forward and communicate its messages more effectively. The rising importance of the media relations should contribute to rebuild public trust and improve the image of the industry.

Is your company communicating effectively with its main stakeholders, both on corporate and product level?
Are your employees representing your brand?
Do you have an up-to-date crisis communication strategy?
How do you increase business performance through various communication channels?

This event brings together a powerful group of Pharma communication experts to discuss these and other daily challenges interactively. Moreover, attending this conference gives you a unique chance to learn how to improve your corporate image, cooperate with the media and make your employees your corporate ambassadors.

Key Speakers:

  • Director of Public Affairs International, Biogen Idec, Switzerland
  • External Communications Manager, AstraZeneca, Poland
  • Communications Manager, Amgen, Italy
  • Communications Director, Merck Sharp & Dohme, Spain
  • HR & Communications Director, Abbott
  • Associate Director Corporate Media Relations EMEA, Pfizer
  • Head of corporate Communications, Pliva Barr Group
  • Head of Corporate PR, Actavis
  • Head of Corporate Communication, Grünenthal Germany
  • Communications Manager, Novo Nordisk, Switzerland & World Diabetes Foundation
  • Director of Communications, Roche France
  • and many others...

Key topics:

  • Find out how effective media relations can contribute to rebuild public trust
  • Discuss how to increase business performance through various communication channels
  • Discover how to communicate with stakeholders when facing crisis and make the crisis work for you
  • Learn best practices for aligning employees with business strategies
  • Clarify the optimal way of cooperating with the media and turn your employees into brand ambassadors

Who should attend:
Vice-Presidents, Directors, Deputy Directors and Heads of Corporate Communication, Internal Communication, Corporate Affairs, Public Relations, Media Relations, Corporate Social Responsibility, Project Leaders, General Managers, Human Resources, Organizational Development, Business Development, Marketing

Request Brochure:

For further information, please visit:
http://www.jacobfleming.com/conferences/life-science/2nd-pharma-corporate-communication

About Jacob Fleming
Jacob Fleming is one of the world's leading business intelligence companies producing business-to-business conferences which consists of current research, market trends, technological developments and applications. Our market-led intelligence allows our customers to make informed decisions for maximum bottom-line impact.

Jacob Fleming offices in Bratislava (Slovakia), Prague (Czech republic), Budapest (Hungary), Barcelona (Spain), Dubai (UAE) and Cleveland (USA) specialize in organizing prestigious international conferences for Europe and GCC region, providing groundbreaking strategies and proven technical expertise in both business functional areas and vertical markets through energy, finance, media, pharmaceutical and telecom sectors.

For further information, please visit www.jacobfleming.com.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Disparities in United States COVID-19 vaccine dist…

When reports showed COVID-19 vaccination rates were lower among racial/ethnic minority groups, most discussions focused on mistrust and misinformation among these populat...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

GSK signs agreement to support pandemic preparedne…

GSK plc (LSE/NYSE: GSK) announced it had signed a framework contract with the European Commission's (EC) Health Emergency Preparedness and Response Authority (HERA) for t...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...